Metfogamma (Metformin Hydrochloride)

Metfogamma belongs to the biguanide class and is used to manage disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels, helping achieve glycaemic targets.
• Polycystic ovary syndrome (off‑label): improves insulin resistance, which can restore ovulatory cycles and reduce androgen levels.
• Prediabetes: delays progression to overt diabetes by improving insulin sensitivity and reducing hepatic glucose output.

• Metformin Hydrochloride acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis. It also increases peripheral insulin sensitivity by enhancing glucose uptake in muscle and adipose tissue and decreasing intestinal glucose absorption, leading to overall lower plasma glucose concentrations.

Metfogamma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite.
• Diarrhea: frequent loose stools, especially during treatment initiation.
• Metallic taste: transient alteration of taste perception.
• Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate, particularly in patients with renal impairment.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatotoxicity: abnormal liver enzymes indicating potential liver injury.
• Vitamin B12 deficiency: may develop with long‑term therapy, leading to anemia.
• Hypoglycaemia: uncommon when used alone but possible when combined with other glucose‑lowering agents.

Before initiating Metfogamma, several safety considerations should be reviewed.

• Renal function assessment: ensure adequate kidney function to avoid accumulation and lactic acidosis.
• Hepatic function monitoring: evaluate liver enzymes, as impaired function can increase risk of adverse events.
• Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia or severe infection.
• Pregnancy and lactation: classified as Category B; use only if benefits outweigh potential risks.
• Vitamin B12 monitoring: periodic testing recommended during long‑term therapy.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metfogamma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging.
• Cimetidine: may raise metformin plasma concentrations, enhancing toxicity.
• Alcohol: excessive intake can potentiate lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• ACE inhibitors and diuretics: can affect renal function, requiring dose adjustment.
• Warfarin: may increase INR, necessitating closer coagulation monitoring.